CAS: 774517-20-3; (S)-Quinuclidin-3-Yl (R)-1-Phenyl-3,4-Dihydroisoquinoline-2(1H)-Carboxylate

该化合物是用于药物分析和质量控制的高纯度参考标准,这种杂质具体与用于治疗过活性膀胱综合症的一种活性药物成分Solifenacin sucnate(API)有关,作为欧洲药店准则中已查明的杂质,对确保最终药物产品的安全和有效性至关重要,该化合物的特点是采用严格的分析方法,包括HPLC和质量光谱测量法,以确认其特性和纯度,其作为定义明确的参考材料的可得性有助于遵守管制要求,协助在药物开发和制造期间进行不纯度特征分析,方法验证和稳定性研究.

结构式图片

欧盟法规

C&L通报

上下游产品

ethyl (R)-1-phenyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (S)-quinuclidin-3-ol 1-phenyl-3,4-dihydroisoquinoline N-phenethylbenzamide (1S,3'S)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydr°Chloride Solifenacin hydr°Chloride (1R,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydr°Chloride

合成工艺路线路线简述

    📜1-苯基-3,4-二氢异喹啉置于sodium Tetrahydroborate,Sodium Hydride,Potassium Carbonate体系中,用 乙醇,二氯甲烷,甲苯 作为反应溶剂,化学反应 60.0H,反应生成 (1R,3S)-索利那新杂质2
    参考文献:Synthesis And Antimuscarinic Properties Of Quinuclidin-3-Yl 1,2,3,4-Tetrahydroisoquinoline-2-Carboxylate Derivatives As Novel Muscarinic Receptor Antagonists
    标题:Synthesis And Antimuscarinic Properties Of Quinuclidin-3-Yl 1,2,3,4-Tetrahydroisoquinoline-2-Carboxylate Derivatives As Novel Muscarinic Receptor Antagonists
    摘要:In The Course Of Continuing Efforts To Develop Potent And Bladder-Selective Muscarinic M-3 Receptor Antagonists,Quinuclidin-3-Yl 1-Aryl-1,2,3,4-Tetrahydroisoquinoline-2-Carboxylate Derivatives And Related Compounds Were Designed As Conformationally Restricted Analogues Of Quinuclidin-3-Yl Benzhydrylcarbamate (8). Binding Assays With Rat Muscarinic Receptor Subtypes Revealed That The Quinuclidin-3-Yl 1-Aryl-1,2,3,4-Tetrahydroisoquinoline-2-Carboxylate Derivatives Showed High Affinities For The M3 Receptor,And Selectivity For The M3 Receptor Over The M-2 Receptor. Of These Derivatives,(+)-(1S,3'R)-Quinuclidin-3'-Yl 1-Phenyl-1,2,3,4-Tetrahydroisoquinoline-2-Carboxylate Monohydrochloride (9B) Exhibited Almost The Same Inhibitory Activity Against Bladder Contraction To That Of Oxybutynin (1),And More Than 10-Fold Selectivity For Bladder Contraction Versus Salivary Secretion,Demonstrating That 9B May Be Useful For The Treatment Of Symptoms Associated With Overactive Bladder Without Having Side Effects Such As Dry Mouth.
    DOI:10.1021/jm050099Q

    海关参考信息

    专利信息


    专利号:US-7741489-B2
    优先权日:2007-03-30
    标题:Process for the synthesis of solifenacin
    发明人:PUIG SERRANO JORDI; CAMPS PELAYO
    权利人:MEDICHEM SA
    摘要:The present invention provides an improved synthetic strategy for the preparation of solifenacin and pharmaceutically acceptable salts thereof.

    专利号:US-2008242697-A1
    优先权日:2007-03-30
    标题 :Process for the synthesis of solifenacin

    专利号:JP-2010523539-A
    优先权日:2007-03-30
    标 题:Improved synthesis of solifenacin

    专利号:CA-2682381-A1
    优先权日:2007-03-30
    标题:An improved process for the synthesis of solifenacin

    专利号:CN-101711248-A
    优先权日:2007-03-30
    标 题 :An improved process for the synthesis of solifenacin

    专利号:KR-20100016116-A
    优先权日:2007-03-30
    标 题 :Advanced Synthesis of Solifenacin

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1021/jm050099q
    摘要:Naito R, Yonetoku Y, Okamoto Y, Toyoshima A, Ikeda K, Takeuchi M. Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists. J Med Chem. 2005 Oct 20;48(21):6597–606. doi: 10.1021/jm050099q.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知